Company NEOVACS

Equities

ALNEV

FR001400MV37

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:24 2024-05-31 am EDT			5-day change	1st Jan Change
0.144 ^EUR	-3.94%		-15.24%	-92.80%

May. 29	Neovacs: mRNA approach validated in preclinical trial	CF
May. 27	Neovacs: collaboration contract with INSERM team	CF

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Number of employees: 22

EUR in Million	2022	Weight	2023	Weight	Delta
Immunotherapy 100.0 %	0	100.0 %	1	100.0 %	+47,868.71%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	0	100.0 %	1	100.0 %	+47,868.71%

Managers	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	20-09-30
Vincent Serra COO	Chief Operating Officer	55	19-02-19
Charlène Masson IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Jean-Jacques Bertrand BRD	Director/Board Member	85	03-05-27
Daniel Zagury FOU	Founder	-	93-04-15
Hugo Brugière CEO	Chief Executive Officer	-	-
Baudouin Hallo BRD	Director/Board Member	-	-
Muriel Haim BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	140	0 ( 0.1248 %)	0	0.1248 %

Name	Equities	%	Valuation
Dominique Catteaux Gestion 0.000000 %	0	0.000000 %	- €
Allianz Global Investors GmbH (France) 0.000000 %	0	0.000000 %	- €
La Mondiale SAM (Investment Portfolio) 0.000000 %	0	0.000000 %	- €
Martin Maurel Gestion Institutionnelle SA 0.000000 %	0	0.000000 %	- €
Uzes Gestion SA 0.000000 %	0	0.000000 %	- €
La Financière Desselligny SA 0.000000 %	0	0.000000 %	- €
Cogéfi Gestion SA 0.000000 %	0	0.000000 %	- €

Neovacs SA

14 rue de la République

75014, Suresnes

http://www.neovacs.fr

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEOVACS	-92.80%	54.92K
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research